Formulation and Optimization of Paclitaxel Loaded Lipid Nanoparticles and Their In Vitro Cytotoxicity Studies Using H1299 Lung Cancer Cell Lines

2019 ◽  
Vol 11 (12) ◽  
pp. 1202-1217 ◽  
Author(s):  
Hiren Khatri ◽  
Nimitt Chokshi ◽  
Shruti Rawal ◽  
Bhoomika Patel ◽  
Mayur M. Patel
Keyword(s):  
Lung Cancer ◽  
Particle Size ◽  
Cell Lines ◽  
Release Kinetics ◽  
Drug Loading ◽  
Lipid Nanoparticles ◽  
In Vitro Cytotoxicity ◽  
H1299 Cell ◽  
Cytotoxicity Studies

Lung cancer is the leading cause of cancer-related death in the world, and approximately 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC). Paclitaxel (PTX) has been widely used for the treatment of NSCLC. It is classified as a BCS class IV drug and offers a low therapeutic index. The present investigation demonstrates development of orally administered PEGylated, PTX loaded solid lipid nanoparticles (PTX-SLNs). A Box-Behnken design was applied to systematically optimize PTX-SLNs. Drug concentration, emulsifier concentration and homogenization pressure were selected as an independent variables, and particle size, % entrapment efficiency (%EE) and % drug loading (%DL) were selected as dependent variables. The particle size of optimized PTXSLNs was found to be 401 ± 12 nm, with %EE of 86.63 ± 2.58%, and %DL of 7.42 ± 0.11%. The developed PTX-SLNs exhibited anti-lipolytic effect due to its stabilization by MPEG2000-DSPE. Moreover, the in vitro GI stability studies revealed good stability of PTX-SLNs in various GI tract media. The in vitro drug release studies revealed controlled release profile with Weibull model release kinetics. In vitro cytotoxicity studies in H1299 cell lines revealed significant decline in IC50 values of PTX-SLNs treated cells as compared to pure drug, thus revealing an improved efficacy of the developed systems.

Lipophilic Prodrug of Floxuridine Loaded into Solid Lipid Nanoparticles: In Vitro Cytotoxicity Studies on Different Human Cancer Cell Lines

2018 ◽  
Vol 18 (1) ◽  
pp. 556-563 ◽  
Author(s):  
Daniela Chirio ◽  
Elena Peira ◽  
Luigi Battaglia ◽  
Benedetta Ferrara ◽  
Alessandro Barge ◽  
...  
Keyword(s):  
Cell Lines ◽  
Solid Lipid Nanoparticles ◽  
Human Cancer ◽  
Lipid Nanoparticles ◽  
In Vitro Cytotoxicity ◽  
Human Cancer Cell ◽  
Human Cancer Cell Lines ◽  
Cytotoxicity Studies ◽  
Lipophilic Prodrug

Development of pH-Dependent Nanospheres for Nebulisation- In vitro Diffusion, Aerodynamic and Cytotoxicity Studies

Drug Research ◽  
2018 ◽  
Vol 68 (12) ◽  
pp. 680-686 ◽  
Author(s):  
Pradum Ige ◽  
Sagar Pardeshi ◽  
Raju Sonawane
Keyword(s):  
Particle Size ◽  
Beclomethasone Dipropionate ◽  
Drug Loading ◽  
Entrapment Efficiency ◽  
In Vitro Cytotoxicity ◽  
Mean Particle Size ◽  
Cytotoxicity Studies ◽  
In Vitro Diffusion ◽  
Ph Dependent

AbstractThe aim of this work was to evaluate the in vitro performance of nebulized nanosuspension formulation when nebulized using ultrasonic nebulizer. The present investigation deals with successful formulation of Beclomethasone dipropionate loaded HPMCP nanospheres prepared by solvent evaporation technique using PEG 400 as a stabilizer. Beclomethasone dipropionate is a water insoluble drug molecule was encapsulated in HPMCP nanospheres to have pH dependent solubility at basic pH for targeted drug delivery in lung and studied for in vitro cytotoxicity and immediate release capability. The synthesized nanospheres were characterized through drug excipient compatibility, surface topography; mean particle size , zeta potential, PDI, entrapment efficiency and drug loading, in vitro diffusion, aerodynamic, in vitro cytotoxicity and stability studies. The mean particle size and PDI of the optimized batch (F1) had 197.6±0.40 nm and 0.324 ±0.35, respectively. The % entrapment efficiency and % drug loading was found to be 86.56±1.32 and 8.30±0.27, respectively. The optimized batch F1 showed % cumulative drug release 94.77±0.24 at 1 h. The formulation showed cell viability up to 91.28%. It can be concluded that, Beclomethasone dipropionate loaded HPMCP nanospheres was found to be safe, stable with significant increase in solubility and bypass the liver.

Solid Lipid Nanoparticles for Topical Delivery of Acitretin for the Treatment of Psoriasis by Design of Experiment

2020 ◽  
Vol 12 (2) ◽  
pp. 4474-4491
Author(s):  
Rajkumar Aland ◽  
Ganesan M ◽  
P. Rajeswara Rao ◽  
Bhikshapathi D. V. R. N.
Keyword(s):  
Particle Size ◽  
Drug Release ◽  
Solid Lipid Nanoparticles ◽  
Drug Loading ◽  
Entrapment Efficiency ◽  
Lipid Nanoparticles ◽  
Tem Analysis ◽  
In Vitro Drug Release ◽  
Solid Lipid

The main objective for this investigation is to develop and optimize the solid lipid nanoparticles formulation of acitretin for the effective drug delivery. Acitretin loaded SLNs were prepared by hot homogenization followed by the ultrasonication using Taguchi’s orthogonal array with eight parameters that could affect the particle size and entrapment efficiency. Based on the results from the analyses of the responses obtained from Taguchi design, three different independent variables including surfactant concentration (%), lipid to drug ratio (w/w) and sonication time (s) were selected for further investigation using central composite design. The  lipid Dynasan-116, surfactant poloxomer-188 and co surfactant egg lecithin resulted in better percent drug loading and evaluated for particle size, zeta potential, drug entrapment efficiency, in vitro drug release and stability. All parameters were found to be in an acceptable range. TEM analysis has demonstrated the presence of individual nanoparticles in spherical shape and the results were compatible with particle size measurements.  In vitro drug release of optimized SLN formulation (F2) was found to be 95.63 ± 1.52%, whereas pure drug release was 30.12 after 60 min and the major mechanism of drug release follows first order kinetics release data for optimized formulation (F2) with non-Fickian (anomalous) with a strong correlation coefficient (R2 = 0.94572) of Korsemeyer-Peppas model. The total drug content of acitretin gel formulation was found to 99.86 ± 0.012% and the diameter of gel formulation was 6.9 ± 0.021 cm and that of marketed gel was found to be 5.7 ± 0.06 cm, indicating better spreadability of SLN based gel formulation. The viscosity of gel formulation at 5 rpm was found to be 6.1 x 103 ± 0.4 x 103 cp. The release rate (flux) of acitretin across the membrane and excised skin differs significantly, which indicates about the barrier properties of skin. The flux value for SLN based gel formulation (182.754 ± 3.126 μg cm−2 h−1) was found to be higher than that for marketed gel (122.345 ± 4.786 μg cm−2 h−1). The higher flux and Kp values of SLN based gel suggest that it might be able to enter the skin easily as compared with marketed gel with an advantage of low interfacial tension of the emulsifier film that ensures an excellent contact to the skin. This topically oriented SLN based gel formulation could be useful in providing site-specific dermal treatment of psoriasis

The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib

2020 ◽  
Vol 20 (6) ◽  
pp. 700-708
Author(s):  
Mitra Korani ◽  
Sara Nikoofal-Sahlabadi ◽  
Amin R. Nikpoor ◽  
Solmaz Ghaffari ◽  
Hossein Attar ◽  
...  
Keyword(s):  
Side Effects ◽  
Cell Line ◽  
Therapeutic Efficacy ◽  
Drug Loading ◽  
Particle Diameter ◽  
In Vitro Cytotoxicity ◽  
Liposomal Formulations ◽  
Cytotoxicity Studies ◽  
Anti Tumor Activity

Aims: Here, three liposomal formulations of DPPC/DPPG/Chol/DSPE-mPEG2000 (F1), DPPC/DPPG/Chol (F2) and HSPC/DPPG/Chol/DSPE-mPEG2000 (F3) encapsulating BTZ were prepared and characterized in terms of their size, surface charge, drug loading, and release profile. Mannitol was used as a trapping agent to entrap the BTZ inside the liposomal core. The cytotoxicity and anti-tumor activity of formulations were investigated in vitro and in vivo in mice bearing tumor. Background: Bortezomib (BTZ) is an FDA approved proteasome inhibitor for the treatment of mantle cell lymphoma and multiple myeloma. The low solubility of BTZ has been responsible for the several side effects and low therapeutic efficacy of the drug. Encapsulating BTZ in a nano drug delivery system; helps overcome such issues. Among NDDSs, liposomes are promising diagnostic and therapeutic delivery vehicles in cancer treatment. Objective: Evaluating anti-tumor activity of bortezomib liposomal formulations. Methods: Data prompted us to design and develop three different liposomal formulations of BTZ based on Tm parameter, which determines liposomal stiffness. DPPC (Tm 41°C) and HSPC (Tm 55°C) lipids were chosen as variables associated with liposome rigidity. In vitro cytotoxicity assay was then carried out for the three designed liposomal formulations on C26 and B16F0, which are the colon and melanoma cancer mouse-cell lines, respectively. NIH 3T3 mouse embryonic fibroblast cell line was also used as a normal cell line. The therapeutic efficacy of these formulations was further assessed in mice tumor models. Result: MBTZ were successfully encapsulated into all the three liposomal formulations with a high entrapment efficacy of 60, 64, and 84% for F1, F2, and F3, respectively. The findings showed that liposomes mean particle diameter ranged from 103.4 to 146.8nm. In vitro cytotoxicity studies showed that liposomal-BTZ formulations had higher IC50 value in comparison to free BTZ. F2-liposomes with DPPC, having lower Tm of 41°C, showed much higher anti-tumor efficacy in mice models of C26 and B16F0 tumors compared to F3-HSPC liposomes with a Tm of 55°C. F2 formulation also enhanced mice survival compared with untreated groups, either in BALB/c or in C57BL/6 mice. Conclusion: Our findings indicated that F2-DPPC-liposomal formulations prepared with Tm close to body temperature seem to be effective in reducing the side effects and increasing the therapeutic efficacy of BTZ and merits further investigation.

Surface Engineered Porous Silicon-based Nanostructures for Cancer Therapy

2012 ◽  
Vol 1416 ◽  
Author(s):  
Adi Tzur-Balter ◽  
Naama Massad-Ivanir ◽  
Ester Segal
Keyword(s):  
Porous Silicon ◽  
Surface Chemistry ◽  
Electrochemical Etching ◽  
Release Kinetics ◽  
Drug Carrier ◽  
Drug Loading ◽  
Nitrogen Adsorption ◽  
Cancer Drug ◽  
Cytotoxicity Studies

ABSTRACTIn this work, nanostructured porous silicon (PSi) hosts, synthesized by electrochemical etching of Si, are designed to carry and release the anti cancer drug, mitoxantrone dihydrochloride (MTX). We study the effect of surface chemistry of the Si scaffold on its properties as a drug carrier. The freshly-etched PSi is modified by surface alkylation using thermal hydrosilylation with 1-dodecene. Fourier-transform infrared spectroscopy and nitrogen adsorption-desorption measurements are employed to characterize the PSi carriers after chemical modification. Both, drug loading efficiency and release kinetics are found to be significantly affected by surface chemistry of the PSi. In vitro cytotoxicity studies on human breast carcinoma (MDA-MB-231) cells show that the MTX released from the PSi hosts maintains its cytotoxic functionality.

P-355 Effect of STI571 on in vitro cytotoxicity of vinorelbine and topotecan in lung cancer cell lines

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S181 ◽  
Author(s):  
Gordana Vlahovic ◽  
Michael J. Kelley
Keyword(s):  
Lung Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
In Vitro Cytotoxicity ◽  
Lung Cancer Cell

scholarly journals Formulation of Solid Lipid Nanoparticles of Cilnidipine for the Treatment of Hypertension

2019 ◽  
Vol 9 (3) ◽  
pp. 212-221 ◽  
Author(s):  
Aparna Bhalerao ◽  
Pankaj Prakash Chaudhari
Keyword(s):  
Particle Size ◽  
Solid Lipid Nanoparticles ◽  
Encapsulation Efficiency ◽  
Drug Loading ◽  
Lipid Nanoparticles ◽  
Water Soluble ◽  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Lipid Nanoparticle

Cilinidipine is a fourth generation N and L-type calcium channel antagonists used alone or in combination with another drug to treat hypertension. Cilnidipine is poorly water -soluble, BCS class II drug with 6 to 30 percent oral bioavailability due to first pass metabolism. So to protect the drug from degradation and improve its dissolution, solid lipid nanoparticles were prepared. Glyceryl monostearate was selected as lipid while span 20: tween 20 were selected as surfactant blends. The formulations were evaluated for various parameters, as percent transmittance, drug content, percent encapsulation efficiency; percent drug loading, In vitro drug release and particle size. Optimized formulation was lyophilized using lactose as a cryo-protectant. The lyophilized formulation was evaluated for micromeritic properties, particle size and in vitro dissolution. It was further evaluated for DSC, XRD, and SEM. Percent encapsulation efficiency and percent drug loading of optimized formulation (F3) were 78.66percent and 9.44percent respectively. The particle size of F3 formulation without drug was 204 nm and with the drug was 214 nm. The particle size of the reconstituted SLN was 219 nm. In DSC study, no obvious peaks for cilnidipine were found in the SLN of cilnidipine indicated that the cilnidipine must be present in a molecularly dissolved state in SLN. In X-ray diffractometry absence of peaks representing crystals of cilnidipine in SLN indicated that the drug was in an amorphous or disordered crystalline phase in the lipid matrix. Thus, solid lipid nanoparticle formulation is a promising way to enhance the dissolution rate of cilnidipine. Keywords: Cilnidipine, Solid Lipid Nanoparticle, Hypertension

scholarly journals An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies

Nanomaterials ◽  
2022 ◽  
Vol 12 (2) ◽  
pp. 250
Author(s):  
Evren Gundogdu ◽  
Emine-Selin Demir ◽  
Meliha Ekinci ◽  
Emre Ozgenc ◽  
Derya Ilem-Ozdemir ◽  
...  
Keyword(s):  
Particle Size ◽  
Zeta Potential ◽  
Cellular Uptake ◽  
Enzyme Inhibitor ◽  
Release Kinetics ◽  
In Vitro Release ◽  
Nanostructured Lipid Carrier ◽  
Loading Capacity ◽  
Cytotoxicity Studies

Imatinib (IMT) is a tyrosine kinase enzyme inhibitor and extensively used for the treatment of gastrointestinal stromal tumors (GISTs). A nanostructured lipid carrier system (NLCS) containing IMT was developed by using emulsification–sonication methods. The characterization of the developed formulation was performed in terms of its particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, loading capacity, sterility, syringeability, stability, in vitro release kinetics with mathematical models, cellular uptake studies with flow cytometry, fluorescence microscopy and cytotoxicity for CRL-1739 cells. The particle size, PDI, loading capacity and zeta potential of selected NLCS (F16-IMT) were found to be 96.63 ± 1.87 nm, 0.27 ± 0.15, 96.49 ± 1.46% and −32.7 ± 2.48 mV, respectively. F16-IMT was found to be stable, thermodynamic, sterile and syringeable through an 18 gauze needle. The formulation revealed a Korsmeyer–Peppas drug release model of 53% at 8 h, above 90% of cell viability, 23.61 µM of IC50 and induction of apoptosis in CRL-1739 cell lines. In the future, F16-IMT can be employed to treat GISTs. A small amount of IMT loaded into the NLCSs will be better than IMT alone for therapy for GISTs. Consequently, F16-IMT could prove to be useful for effective GIST treatment.

IN VITRO CYTOTOXICITY STUDIES ON ISOLATED AND PURIFIED COMPOUNDS FROM CHRYSOPOGON ZIZANIOIDES CHLOROFORM EXTRACT ON VERO AND HCT-116 CANCER CELL LINES

2021 ◽  
pp. 37-39
Author(s):  
Sajusha Duguluri ◽  
Selvakumar S
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Chloroform Extract ◽  
In Vitro Cytotoxicity ◽  
Chrysopogon Zizanioides ◽  
Human Colorectal Cancer Cell ◽  
Cytotoxicity Studies ◽  
Hct 116

The main objective of this study is to investigate the cytotoxic potential of four puried compounds (compounds 1,2,3 and 4) from medicinal plant Chrysopogon zizanioides L were investigated. Successive solvent extraction of Chrysopogon zizanioides in chloroform was done. The extract were tested against the normal cell lines (Vero) human colorectal cancer cell lines (HCT-116) using the thiazolyl blue test (MTT) assay. The chloroform fractions of Chrysopogon zizanioides had shown the signicant results against Vero and HCT-116 tumor cell lines. The IC50concentration of the selected puried compounds C1, C2, C3, and C4 against HCT 116 were 79.06 µg/ml, 84.13 µg/ml, 94.36 µg/ml and 68.47µg/ml, respectively. Whereas the IC50concentration of the selected puried compounds C1, C2, C3, and C4 against Vero were 130.30µg/ml, 157.36µg/ml, 160.48µg/ml and 255.28µg/ml, respectively. Among all the tested compounds, compound four can be considered as potential sources of anti-cancer compounds. Additional studies are necessary for more extensive biological evaluations.

Sign in / Sign up

Export Citation Format

Share Document